CURRICULUM VITAE

CURRICULUM VITAE

LYUBA VARTICOVSKI, M.D.

Staff Clinician, Office of the Director

Adjunct Scientist, Laboratory of Human Carcinogenesis

Center for Cancer Research, National Cancer Institute, Bethesda, MD

37 Convent Drive, Room 3060, Bethesda, MD 20892

e-mail: varticol@mail.nih.gov

Education:

1976 Medicine and Surgery (MD), University of Valle, Cali, Colombia

1967 B.A. Analytical and Laboratory Chemistry, Honor student, Tyumen, Siberia, Russia

Postgraduate training:

1986-1988 Research Fellow, Department Physiology, Tufts University School of Medicine,

Boston, MA

1985-1986 Research Fellow, National Cancer Institute, NIH/NCI, Bethesda, MD

1982-1985 Clinical Fellow Hematology/Oncology, New England Medical Center, Boston

1979-1982 Intern and Resident in Medicine, Albany Medical Center Hospital, Albany, NY

1977-1979 Research Fellow, Division Hematology and Oncology, U. of Utah MC, Salt Lake City, UH

1976-1977 General Medical and Surgical practice year (Pay-back requirement), Risaralda,

Colombia.

Professional Experience:

02/2003-present: Staff Clinician, Center for Cancer Research, NCI, NIH, Bethesda, MD

02/2003-present: Adjunct Scientist, Laboratory of Human Carcinogenesis, CCR, NCI

10/2001-10/2002 Senior Visiting Fellow, Laboratory of Human Carcinogenesis, NCI,

Bethesda, MD

10/2001-12/2003 Associate Professor, Clinical Staff, New England Medical Center,

Boston, MA

06/1997-12/2003 Associate Professor in Medicine and Physiology, TUSM, Boston, MA

10/2001-02/2003 Associate Professor, Tufts U. School of Nutrition, Science and Policy,

Boston, MA

02/1990-02/1993 Director, Clinical Hematology Laboratory, St. Elizabeth’s MC

10/1989-10/2001 Clinical Staff, Division Hematology/Oncology, St. Elizabeth’s MC,

Boston, MA

10/1989-10/2001 Associate Investigator, Department of Biomedical Research, St.

Elizabeth’s Medical Center, Boston, MA

07/1989-07/1997 Assistant Professor in Medicine and Physiology, TUSM

07/1988-10/1989 Instructor in Medicine, Tufts University School of Medicine, Boston, MA

01/1987-07/1988 Visiting Scientist, NCI, NIH, Bethesda, MD

Medical Licenses:

2003-present Medicine, Maryland

1982-2003 Medicine, Massachusetts

Board Certification:

1984- Internal Medicine

1986- Hematology

1987- Board Eligible in Oncology

Academic Appointments and Clinical Rsponsibilities:

02/2003-present: Staff Clinician, NCI, Warren Grant Magnuson Clinical Center, NIH,

Bethesda, MD. Develop and participate in Phase I/II clinical trials.

10/2001-12/2003 Clinical Staff, Department of Medicine, Division of Hematology and

Oncology, New England Medical Center, Boston, MA. 3-4 months/year 30-bed

service inpatient coverage.

10/1989-10/2001 Clinical Staff, Department of Medicine, Division of Hematology and

Oncology, St. Elizabeth’s Medical Center, Boston, MA. Weekly outpatient general

Oncology and chronic leukemias clinic; 4 months/year of Hematology and Oncology inpatient services.

Committee Assignments:

2003-present: Molecular Targeting Steering Committee, NCI, NIH

2007-present: Staff Clinicians Career Development Committee, Staff Scientists and

Staff Clinicians Association, CCR, NCI, NIH

2007-present: TRIG, trans-NIH translational research interest group

2007 and 2008 Retreat Committee, SS/SC Association, CCR, NCI, NIH

2003-2007 Protocol Review and Monitoring Committee (PRMC), CCR, NCI, NIH

2005-2007 Organizational Committee, SS/SC Association, CCR

2004-2005 Proteomics Steering Committee, CCR, NCI, NIH

2004-2005 Patient Outreach and Accrual Committee, NCI, NIH

1997-2000 Quality Assurance, Clinical Activities, Division of Hematology/Oncology,

St. Elizabeth’s Medical Center, Boston, MA

1996-1998 Chair, Scientific Affairs Committee, TUSM, Charlton Fund

1998-2000 Scientific Affairs Committee, Tufts U. School of Medicine Charlton Awards

1996-2000 Russian Steering Committee, St. EMC, Boston, MA

1996-1998 Chair, Institutional Animal Care and Use Committee, St. EMC, Boston, MA

1990-1998 Research Awards Committee, St. EMC, Boston, MA

Other Major National Committee Assignments:

1996-1999 National Chronic Myelogenous Leukemia Study Group

2007 - Biological Therapeutic Agents Subcommittee of the Experimental and Molecular Therapeutics Section of the 2007 Program Committee Biological Therapeutic Agents Subcommittee, AACR

Teaching:

2000-2001 Demystifying Medicine for PhD’s, NIH, Bethesda, MD

1997-2001 Membrane Biology and Biochemistry, Sackler School for Graduate Studies,

Tufts U. School of Medicine, Boston, MA

1997-2001 Biochemistry and Membrane Biology, Sackler School for Graduate Studies,

Tufts U. School of Medicine, Boston, MA

1993-2002 Pathobiology of Leukemias, Department of Physiology, Sackler School,

Tufts U. School of Medicine, Boston, MA

1990-1998 Hematopathology and Introduction to Basic Sciences, Heme/Onc Fellows, St.

Elizabeth’s Medical Center, Boston, MA

1994-1996 Signal transduction course, Pharmacology, Tufts U. School of Medicine,

Boston, MA, Boston, MA

1991-1997 Signal Transduction Pathways. U. of Florence, Italy

Fellowships received

1985-1988 USPHS Individual Research Fellowship Award, NEMC, Boston, MA

1974 Exchange Student Fellowship, U. of Utah School of Medicine, Salt Lake City, UH

Honorary Appointments:

2006-2008 Secretary, Staff Scientist and Staff Clinicians Association, Bethesda, NCI

2003-2008 Chair, Educational Committee, Russian-American Medical Association

2000-2003 Board of Directors, Jewish Family & Children’s Services

2000-2003 Council member, Combined Jewish Philanthropies in Massachusetts

1997-2005 Secretary, Henry Platt Science Laboratory for Children, Boston, MA

1999-2003 Member of the Board, Camp Hill Foundation, MA Chapter

1994-1999 Founding Director, Association of Russian-Speaking Physicians and other

Medical Professionals in Massachusetts.

NIH Grant Reviewer

2/97; 8/97; 10/97; 12/97; 4/98; 8/98; 9/98; 1/99; 4/99; 10/99 PO1 Reviews/Site visits; 12/99; PAR98-096 Angiogenesis Study Section; RFA CA00-001 Molecular Target Validation/Angiogenesis Study Section

Reviewed Manuscripts for:

American J. of Hematology, Blood, Immunology, Oncogene, Circulation, Circulation Research, J. Vascular Research, J. National Cancer Institute, Cancer Research, Clinical Cancer Research, Coronary Artery Disease, Thrombosis and Hemostasis.

Graduate Student Thesis Committee

Linda Hong (1997, Brent Cochran, PI) Physiology, TUSM, Boston, MA

Wen, Shih-Te (1997, Richard VanEtten, PI) Genetics, Harvard U., Boston, MA

Wey, May (1999, Laura Liscum, PI) Physiology, TUSM, Boston, MA

Charles Plant (2001, W. Bachovchin, PI) Physiology, TUSM, Boston, MA

Current Staff:

2004 - present: AI Robles, Ph.D., Staff Scientist

2004- present: Post-baccalaureate fellow (CRTA)

Mentoring NCI Intramural students and fellows:

2007-present: M. Carlson, pre-CERTA, MTU, LHC, CCR, NCI

2006-2008 C. Salcido, pre-CERTA, LHC, CCR, NCI

2005-2007 M. Wright, CERTA, LHC, MTU, CCR, NCI (PhD Graduate Student, BU, Boston, MA)

2005-2007 S. Feis, Special Volunteer, W. Churchill HS, CCR, NCI (Freshman, Yale)

6-8/2007 Kathy Chen, (softmore, science major, U. Maryland)

6-8/2006 Karen Cress (3d year Medical Student, U. Texas)

6-8/2006 M. Teniola (3d year Medical Student); H. Simonds (senior, W. Churchill HS)

6-8/2005 Lucien Cuenca (currently CERTA, LCB, CCR),

2003-2004 K. Beck, MD, Research Fellow LHC, CCR (Clinical Fellow, Surgery, CCR, NCI)

6-8/2005 Y. Linares, Andover HS (currently Pre-Med, Columbia U); M. Richardson, BS (currently PhD student, Department of Biochemistry, U Mississippi)

Mentoring prior to 2003:

Trained 12 Postdoctoral Fellows, 4 Clinical Fellows, and 6 Medical Students (1989-2003).

Among previous trainees: L. Pandite, MD, Director Oncology, Glaxo, USA; M. Pawlowsky, MD Director, Hematology, Buenos Aires, Argentina; T. Oo, MD, Assistant Professor, TUSM; Boston, MA; T. Kagawa, PhD, Assistant Director, Japanese National Institute of Animal Sciences, Japan; M. Susa, Senior Scientist, Novartis, Basel, Switzerland; Y. Wang, MD/PhD, Harvard Medical School; D. Harrington, MD/PhD, Professor, Department of Medicine, U. of Nebraska.

Educational activities

2003 - present: Designed and developed a postgraduate course for CCR: Translational Research in Clinical Oncology (TRACO). Lectured, and continue to participate in selection of faculty and topics in collaboration with. T. Moody and J. Wiest

Grants and Funding Received

2005-2007 Bed-to-Bedside Award, Lung cancer stem cells, NIH

2007-2009 BTEP/ISTC (Department of State) Exploration of biologically active

natural products in Kazakhstan, (J. McMahon, co-PI)

1998-2002 RO1, NIDDK: Role of PI 3-kinase in vesicular trafficking

1990-2001 RO1, NCI: Role of PI 3-kinase in hematopoietic malignancies

1996-2000 DOD award: Role of angiopoietins in breast cancer-associated angiogenesis

Awards

2008 – Nominated for Elisabeth and John Cox Award for innovations in Cancer,

Georgetown University, Washington, DC

2006 – CCR, NCI, NIH: Mentoring summer students award

2006 – Humanitarian award for Russian-American Medical Cooperation, World Russian

Forum, US Senate, Washington, DC

2005 - Most Valuable Person Award, Russian American Medical Association, Washington,

2003 - Honorary member, National Center of Hematology, Moscow, Russia

1992-1997 Visiting Professorship, University of Florence, Florence, Italy

1980 - Teaching award, Medical Resident, Albany Medical Center, Albany, NY

1973 - Best student of the Year, U. of Valle Medical School, Cali, Colombia

1967 Silver medalist, School #26, Tyumen, Siberia, Russia

Patents

1. Varticovski, L. “Hyperthermia for Treatment of Chronic Myelogenous

Leukemia”. US and International Patent No: 4.8695

2. Varticovski, L. “Use of Water-Soluble HPMA Copolymer–Wortmannin

Conjugate to Block Phosphoinositide 3-Kinase Activity (pending).

3. C. Harris, l. Varticovski, He, P. W. Travis“Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer (NIH Ref.: E-248-2002/0-PCT-02)

Employee Invention Reports/Licenses awarded

2006: “Cell preservation for transplantation of genetically engineered mouse tumors”. Licensed to NCI

Collaborations: NIH Intramural

Curtis C. Harris, Phillip A. Dennis, Susan Bates, Cynthia Dunbar (NHLBI), and Ron McKay (NINDS), NIH: Bed-to-Bedside award, Lung Cancer Stem Cells

Suresh Ambudkar (LCB, CCR): Role of ABC transporters in lung cancer stem cells

Illona Linnoila (CCBB, CCR): Study of lung cancer stem cells in CC10-Tag mouse model

Paul Goldsmith (OD, CCR): Validation of novel biomarkers for lung cancer

Glenn Merlino (LCRC, CCR): Studies of genetically engineered mouse tumors; development of dual label vectors for study tumor biology and translational research

Yves Pommier (CCR): Studies of cell cycle control and drug interactions of novel Topoisimerase I inhibitors

Collaborations: Ongoing Extramural

Daniel Tenen, MD: Study of lung cancer stem cells in genetically engineered CEBPa KO lung cancer mouse model. BIDMC, Harvard Medical School, Boston, MA

Harold Varmus, MD: Study of lung cancer stem cells in genetically engineered EGFR lung cancer mouse models, MSKCC, New York, NY.

William D. Travis, MD: Lung cancer biomarkers, MSKCC, New York, NY

James Weiley, MD: Lung cancer stem cells, Ohio State University, OH

Chiosis, Gabriela, PhD: Mechanisms of Action of Synthetic HSP90 inhibitors, MSKCC, New York, NY

Ana Maria Cuervo, PhD: Studies of molecular targeted agents on autophagy and ER stress. Albert Einstein School of Medicine, NY

Melinda Hollingshead (DTP, NCI): Preclinical drug testing in xenografts and genetically engineered mouse tumors; validation of lung cancer for transplantation and generation of Luciferase-labeled cells.

Publications:

1- Varticovski, L., Kushner, J.P. and Burnham, B.F. Biosynthesis of Porphyrin Precursors. J. Biol. Chem. 1980; 255: 3742-3744

2- Varticovski, L., Kushner, J.P. and Burnham, B.F. Biosynthesis of PorphyrinPrecursors: Studies on Mammalian L-Alanine/g-Dioxovaleric Acid Aminotransferase. Int. J. Biochem. 1980; 12: 739-744

3- Varticovski, L., Pick, A.I., Shattner, A., and Shoenfeld, Y. Anti-Platelet and anti-DNA IgM in Waldenstrom Macroglobulinemia and ITP. Am. J. of Hematology 1987; 24: 351-355

4- Varticovski, L., Chahwala, S.B., Whitman, M., Cantley, L., Chow, P., Sinclair, L.K. and Pepinski, B.R. Location of Sites in Human Lipocortin I Phosphorylated by Protein Tyrosine Kinases, and Protein Kinases A and C. Biochemistry 1988; 239: 3682-3690

5- Varticovski, L. and Ling, L. Protein-tyrosine kinases and Signal Transduction. Progress in Liver Disease. 3^d edition, Hans Popper, Editor. Raven Press, 1989

6- Auger, K.,Carpenter, C., Cantley,L. and Varticovski, L. PtdIns 3-kinase Activity in the Yeast. J. Biol. Chem. 1989; 264: 20181-20184

7- Pierce, J.H., Ruggiero, M., Fleming, T.P., Di Fiore, P.P., Greenberger, J.S., Varticovski, L., Schlessinger, J., Rovera, J. and Aaronson, S.A. Signal Transduction Through EGF Receptor in IL-3-dependent Hematopoietic Cells. Science 1988; 239: 628-630

8- Varticovski, L., Drucker, B., Morrison, D., Roberts, T. and Cantley, L. The Colony Stimulating Factor-1 Receptor Associates with and Activates PtdIns 3-kinase. Nature 1989; 342: 699-702

9- Varticovski L., Daley GQ., Jackson P, Baltimore D. and Cantley L. Activation of Ptd Ins 3-kinase in cells expressing abl oncogene variants. Mol. Cell. Biol. 1991; 11: 1107-1113

10- Remillard, B., Petrillo, R., Maslinski, W., Tsudo, M., Strom, T.B., Cantley, L., and Varticovski, L. IL-2 Receptor Regulates Activation of PI 3-kinase. J. Biol. Chem. 1991; 266: 14167-14170

11- Susa, M., Keeler, M. and Varticovski, L. PDGF Activates Membrane-associated PI 3-kinase and Mediates its Translocation from Cytosol. J. Biol. Chem. 1992; 267: 22951

12- Mosseri, M. Fingert, H., Varticovski, L., Chokshi, S., Isner, J. Evidence that Myocardial Ischemia Resulting from 5-FU Chemotherapy is due to Protein Kinase C-Mediated Vasoconstriction. Cancer Research 1993; 53: 1-6

13- Exley, M. Peter, M. Sancho, J., Terhorst, C. and Varticovski, L. Association of PI 3-kinase with a Specific Sequence of the T Cell Receptor z Chain is Dependent on T Cell Activation. J. Biol. Chem. 1994; 269: 15140-15146

14- Varticovski, L. et al., Role of Phosphatidylinositol 3-kinase in Transformation. Biochem. Biophysica Acta. 1994; 1226: 1-11

15- Misra, S., Ghosh, A. and Varticovski, L. Naturally-Occuring Ether-Linked PC Activates PI 3-kinase and Stimulates Cell Growth. J. Cell. Biochem. 1994; 55: 1-8

16- Kanazawa, T., Keeler, M., and Varticovski, L. Serine-rich Region of the IL-2 Receptor ß chain is Required for Activation of PI 3-Kinase. Cellular Immunol. 1994; 156: 15-24

17- Harrison, D. and Varticovski, L. Association of Shc with PI 3-kinase in Chronic Myelogenous Leukemia Cells. Oncogene 1995; 10: 1385-1391

18- Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, Isner JM. Hypoxia induces VEGF in cultured human endothelial cells. J Biol Chem. 1995 270:31189-95

19- Hutchcroft, J.E., Franklin, D.P., Tsai, B., Harrison-Findik, D., Varticovski, L. and Bierer, B.E. Phorbol Ester Inhibits Phosphatidylinositol 3-Kinase Activation by Association with CD28, a T-Cell co-receptor. Proc. Natl. Acad. Sci., USA 1995; 92: 8808-8812

20- Ai, Z., Susa-Spring, M., Misra, M., Cohen, C. and Varticovski, L. Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation. Exp. Cell Research 1995; 219: 454-460

21- Atsushi, N., Brogi, E., Kearny, M., Kim, E., Wu, T., Couffinhal, T., Varticovski, L., and Isner, J. Hypoxia Induces Vascular Endothelial Growth Factor in Endothelial Cells. J. Biol. Chem. 1995; 270: 31189-31195

22- Gatmaitan, Z., Varticovski, L., Ling, L., Michelsson, R., Steffan, A-M., and Arias, I. M. Studies on Fenestral Contraction in Rat Liver Endothelial Cells Am. J. of Pathology 1996; 148: 2027-2041

23- Jain, S.K., Susa-Spring, M., Carlesso, N., Druker, B. and Varticovski, L. BCR/abl-induced activation of PI 3-Kinase in the absence of a direct interaction with p85 SH2 domain. Blood 1996; 88: 1542-1550

24- Frank, D. and Varticovski, L. BCR/abl Leads to Constitutive Activation of STAT Proteins. Leukemia, 1996; 10: 1724-1730

25- Brogi, E., Schatteman, G., Wu, T., Kim, E., Keyt, B., Varticovski, L., Isner, J. Hypoxia-InducedParacrine Regulation of Vasular Endothelial Growth Factor Receptor Expression. J. Clin. Invest. 1996; 97: 469-476

26- Rani, S.S.C., Wang, F., Futor, E., Berger, A., Wu, J., Sturgill, T.W.,Varticovski, L. and Spiegel, S. Divergence in Signal Transduction Pathways for Platelet-derived Growth Factor (PDGF) and Epidermal Growth Factor (EGF) Receptors. J. Biol. Chem. 1997; 272: 10777-10783

27- Marucci, L., Varticovski, L. and Arias, I. Effect of Xantine Analog on Human Hepatocellular Carcinoma Cells (Alexander) in Culture and in Xenografts in SCID Mice. Hepatology 1997; 26: 1195-1202

28- Exley, M. and Varticovski, L. Evidence for PI 3-kinase-Depndent TCR Signal Transduction. Molecular Immunology 1997; 34: 221-226

31- Jain, S.K., Langdon, W.Y. and Varticovski, L. Tyrosine Phosphorylation of p120^cbl in BCR/abl Transformed Cells Mediates an Enhanced Association with Phosphatidylinositol 3-Kinase. Oncogene 1997; 14: 526-535

32- de Aos IE, Metzger M, Exley M, Dahl C, Misra S., Zheng D., Varticovski L, Terhorst, C. and Sancho, J. Tyrosine Phosphorylation of the CD3-e Subunit of the T Cell Receptor Mediates Enhanced Association with Phosphotidylinositol 3-Kinase in Jurkat T Cells. J. Biol. Chem. 1997; 272: 25310-25358

33- Misra, S. Ujhazy, P. Gatmaitan, Z., Varticovski, L. and Arias, I. Role of PI Kinases in TC-Induced Trafficking of ATP-Dependent Canalicular Transporters in Rat Liver. J. Biol. Chem.1998; 273: 1278-1284

34- Misra, S. Ujhazy, P. Varticovski, L. and Arias, I. Phosphoinositide 3-kinase Activity is Required for Bile Canalicular ATP-dependent Secretion of Taurocholate and Non Bile Acid Organic Anions. Proc. Natl. Acad. Sci., USA 1999; 96: 5814-5819.

35- Fujikawa, K., Presman, E., Isner, J. and Varticovski, L. Tie 1 and Tie 2 Expression Following Balloon Injury of Rat Carotid Artery. J. Vascular Research, 1999, 36: 272-281

36- Fujikawa, K., deAos, I., Jain, S.K., Presman, E. Christensen, R.A. and Varticovski, L. Role of PI 3-kinase in Angiopoietin-1-Mediated Migration and Attachment-Dependent Survival of Endothelial cells. Exp. Cell. Res. 1999; 253:663-672

37- Jain, S.K., de Aos, I.E., Inai, Y., and Varticovski, L. Downregulation of p210^BCR/abl Tyrosine Kinase Activity in Hematopoietic Cells by Mild Hyperthermia. Leukemia 2000 14:845-852

38- Roumiantsev, S., deAos, I.E., Ilaria, R.L., Varticovski, L. and Van Etten, R.A. The SH2 Domain of Bcr/Abl is Required for Efficient Induction of CML-like Disease in Mice but not for Lymphoid Leukemogenesis or Activation of PI 3-Kinase. Blood 2001; 97: 4-13.

39- Harrison-Findik, D., Misra, S., Jain, S.K., Keeler, M.K., Powell, K.A. Malladi, C.S., VarticovskiL., and Robinson, P.J., Dynamin Inhibits PI 3-kinase in Hematopoietic Cells. Biochem Biophis Acta, 2001, 1538: 10-19

40- Christensen, R.A., de Aos, I. and Varticovski, L. Synthesis and Signaling through D-3 Phosphoinositides. The Liver. Biology and Pathobiology. 4^th Edition; Lippincott, Wilkins and Wilkins, 2001, 145-155.

41- Powers, J., Misra, S., Varticovski, L. and Tishler, A. Mitogenic Signaling by Cyclic AMP in Chromaffin Cells Involves PI 3-kinase Activation. J Cell Biochem. 2001, 81, 89-

42- Kwan, C-P., Venkataraman, G., Shriver, Z., Raman, R., Varticovski, L. and Sasisekharan R. FGF Dimerization through Molecular Engeneering: Evidence of FGF2 Dimerization. J. Biol. Chem. 2001, 276: 23421-23429.

43- Christensen, R.A., Fujikawa, K., Madore, B, Oetgen, P. and Varticovski, L. NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: A mechanism for Tie2 regulation during hypoxia. J. Cell. Biochem. 2002, 85:505-15.

44- Kagawa T, Varticovski L, Sai Y, Arias IM. Mechanism by which cAMP Activates PI 3-Kinase and Increases Bile Acid Secretion in WIF-B9 cells. Am. J. Physiol. 2002, 283: C1655-1666.

45- Misra S, Varticovski L, and Airas IM. Mechanism cAMP induces bile secretion in rat liver and canalicular membrane vesicles. Am. J. Physiol. 2003, 285: G316-24.

46- Shklovsky-Kordi N, Zingerman B, Rivkind N, Goldberg S, Davis S, Varticovski L, Krol M, Kremenetzkaia AM, Vorobiev A, Serebriyskiy I. Computerized case history - an effective tool for management of patients and clinical trials. Health Technol Inform. 2004; 116:53-8

47- Wang, Y., Pampou, S., Mitchell. K. Fujikawa, K. and Varticovski, L. Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC beta. J. Cell. Physiology 2004, 198:53-61

48- Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Mol. Cell Biol 2004, 24: 4685-95.

49- Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, and Grant S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and –resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 2004, 63:2118-26

50- Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, Woychik RP, Yancopoulos GD, Young SG, Zambrowicz B. The knockout mouse project. Nat Genetics. 2004; 36: 921-4.

51- He P, Varticovski L, Bowman ED, Fukuoka J, Welsh J, Miura K, Jen J, Gabrielson E, Brambilla E, Travis EW, and Harris CC. Identification Carboxypeptidase E and g-Glutamyl Hydrolase as Biomarkers for Pulmonary Neuroendocrine Tumors by cDNA Microarray. Human Pathology, 2004, 35:1196-209

52- Staib F, Robles AI, Varticovski L, Wang XW, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Galle PR, and Harris CC. The p53 tumor suppressor network is a key responder to micro-environmental components of chronic inflammatory stress.

Cancer Res. 2005, 65:10255-64.

53- Nunez N, Rosenberg J, Oh WJ, Perella C, Anver M, Pekins SN, Varticovski L, Hursting SD, and Vinson C. Accelerated Tumor Formation in a Fatless Mouse with Type 2 Diabetes and Inflammation. Cancer Res. 2006, 66: 5469-5476.

54- Antony S, Agama KK, Miao Z-H, Hollingshead MG, Holbek SL, Wright MH, Varticovski L, Nagarayan M, Morell A, Cushman M, and Pommier Y. Bisindenoisoquinoline NSC 727357, a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharm, 2006, 10:1124-1129.

55- Robles AI, Wright MH, Gandhi B, Feis S, Hanigan CL, and Varticovski L. Schedule-dependent Synergy between the HSP90 inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG) and Doxorubicin restores apoptosis to p53-mutant lymphoma cells. Clin Cancer Res. 2006, 12; 6547-56.

56- Varticovski L, Hollingshead MG, Robles AI, Carter JP, Borgel SP, Stotler H, Bonomi CA, Anver MR, Nunez N, Hursting S, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield L, and Barrett JC. Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Clin Cancer Res. 2007, 13: 2168-77

57- Varticovski L, and Robles AI. Harnesing genetically engineered mouse models for drug development. Frontiers in Toxicology, Chemico-Biological Interactions. 2007, 171:159–164

58- Chen X-C, Yu B, Dong JC, Gui Y-X, Chen L, Varticovski L, and Wang XW. A Phase II Clinical Trial with Cytotropic Heterogeneous Molecular Lipids (CHML®) for Patients with Hepatic Malignancies. Anticancer Research, 2007, 27:1593-600

59- Shen JC, Kumamoto K, Unoki M, Varticovski L, Pedeux R, and Harris CC. Regulation of cell spreading and migration by candidate tumor suppressor ING4. Cancer Res. 2007, 67: 2552-8.

60- Hursting SD., Nunez NP, Varticovski L, and Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res. 2007, 67: 2391-3.

61- Antony S, Agama KK, Miao ZE-H, Hollingshead MG, Holbek SL, Wright MH, Varticovski L, Nagarajan M, Morell A, Cushman M, and Pommier, Y. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007, 67:10397-411

62- Nunez N, Perkins S, Smith N, Berrigan D, Varticovski L, and Hursting SD. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer, 2007 (in press).

63- Pine S, MarshallB, and Varticovski L. Lung Cancer Stem Cells. Special Edition of Cancer Biomarkers. Stem Cells and Cancer. 2007, in press

64- Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, and Varticovski L. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer, 2008, in press.

65- Wright MH, Calcagno, AM, Sallcido, CD, Carlson, MD, Amudkar, SV, and Varticovski, L. Brca1 breast tumors contain CD133+ and CD44+/24- cells with cancer stem cell characteristics. Breast Ca Res, 2008 in press

66- Koll TT, Feis SF, Wright MH, Teniola MM, Richardson MM, Robles MM, Bradsher J, Capala J, and Varticovski L. HSP90 inhibitor, 17-DMAG, radiosensitizes lung cancer cells by blocking base excision repair and ATM-mediated DNA repair.

Mol Cancer Ther, 2008, in press

67- VarticovskiL, Pine S, Salcido CD, Robles AI, LaRochelle A, Dunbar C, and Harris CC. Characterization of tumor-initiating cells in SP fraction from small cell lung cancer. 2008 (in preparation)

Book Chapters and Reviews

1- Varticovski, L. and Ling, L. Protein-tyrosine kinases and Signal Transduction.

Progress in Liver Disease II. Hans Popper, Editor. Raven Press, 1989 421-436

2- Varticovski, L. et al., Role of Phosphatidylinositol 3-kinase in Transformation.

Biochem. Biophys. Acta. 1994; 1226: 1-11

3- Christensen, R.A., de Aos, I. and Varticovski, L. Synthesis and Signaling through D-3

Phosphoinositides. The Liver. Biology and Pathobiology. 4^th edition; Lippincott, Wilkins and Wilkins, 2001; 4: 495-510

4- Hursting SD., Nunez NP, Varticovski L. and Vinson C. The Obesity-Cancer Link:

Lessons Learned from a Fatless Mouse. Cancer Res. 2007; 67: 2391-3.

5- Robles AI and Varticovski L. Harnesing genetically engineered mouse models for

drug development. Frontiers in Toxicology, Chemico-Bio Interactions. 2007; 2:8-12

6- Pine, S, MarshallB, and Varticovski, L. Lung Cancer Stem Cells. Special Edition of

Cancer Biomarkers. Stem Cells and Cancer review, 2007 (in press).

Selected Abstracts:

1- Antony, S, Agama, KK, Miao, ZE-H, Hollingshead, M, Holbek, SL, Wright, MH, Varticovski, L, Nagarajan, M, Morell, A, Cushman, M, Pommier, Y. Novel Indenoisoquinolines NSC 727357 and NSC 724998 produce persistenc topoisomerase I cleavage complexes and overcome multidrug resistance. AACR-NCI-EORTC International Conference, 2007

2- Varticovski Lyuba, Melinda Hollingshead, Mollie H. Wright, Xiaolin Wu, James Cherry, David Munroe, and Ana I. Robles. Search for Human Correlates in Tumors from Genetically Engineered Mouse Models. AACR, January 2007

3- VarticovskiLyuba, Mollie H. Wright, Eloisi Caldas-Lopes, Gabriela Chiosis, and Ana I. Robles. Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin’s Lymphoma Cell Lines. American Society for Hematology, 2007

4- Vinogradova Yulia E, I N Lutsenko, R S Samoilova, I B Kaplanskaya, Ivan A Vorobiev, Boris V Zingerman, N B Rijicova, Nikita E Shklovskiy-Kordi, E A Giliazitdinova, Oleg V Margolin, D C Maryin, Alexandra Krementskaya, S K Kravchenko, Lyuba Varticovski and Andrei I Vorobiev. Classification and survival of 179 patients with T- and NK-cell lymphomas at the Federal Research Hematology Center of Russian Academy of Medical Sciences: a retrospective study. American Society for Hematology, 2007

5- Shen, JC, Kumamoto, K, Unoki, M, Varticovski, L, Pedeux, R, Harris CC Regulation of cell spreading and migration by candidate tumor suppressor ING4. AACR, Washington, DC 2006

6- Tran, T, Feis, S, Robles, AI, Varticovski, L, Capala, J. HSP90 inhibitor, 17-DMAG, enhances radiosensitivity of human cancer cells ACR, Washington, DC 2006

7- Robles, AI, Wright, MH, Ghandi, B, Feis, S, Harris, CC, Varticovski, L Preclinical evidence of synergism between DNA damaging agents and the HSP90 Inhibitor, 17-DMAG, in tumors with mutant p53 American Association for Cancer Research, Washington, DC 2006

8- Lyuba Varticovski, Melinda Hollingshead, Mollie H. Wright, Xiaolin Wu, James Cherry, David Munroe, and Ana I. Robles. Search for Human Correlates in Tumors from Genetically Engineered Mouse Models. American Association for Cancer Research, Los Angeles, CA 2007.

9- Varticovski, L, Hollingshead, M, Robles, A, Merlino, G, Hunter K, Green, J, Steeg, P, Barrett, JC Drug testing in transgenic mouse models, Frontiers in Toxicology, Chicago, IL, 2006

10- Varticovski, L, Richardson, M, Robles, A. Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 inhibitors. 2005 JCO, ASCO Annual Meeting Proceedings. 23: 3202

11- Varticovski, L., L. Neckers, C. C. Harris and A. I. Robles, CCR, NCI, Bethesda, MD. HSP90 Inhibitors Reverse Resistance to Doxorubicin in p53-Null and Mutant Cells. ASH, 2003

12- Roumiantsev, S, de Aos, I.E., Varticovski, L Ilaria, R.L., and Van Etten. R.A., StEMC and Harvard MS, Boston, MA Src Homology 2 Domain mutations decrease the intrinsic tyrosine kinase activity of Bcr/Abl and attenutate induction of CML-like myeloproliferative disease in mice, but do not cause qualitative defects in known signaling pathways. American Society of Hematology, 2002.

13- Staib, F, Robles, AI, Varticovski, L, Wang, XW, Hussain, PS, Harris, CC p53-dependent gene expression profiles in response to different types of cellular stress. Laboratory of Human Carcinogenesis, NCI, NIH 11^th Annual Meeting of the Society for Free Radical Biology and Medicine, 2003

14- Mitchell. K. Kagawa, T. and L. Varticovski, L. cAMP is a Novel Survival Factor for Endothelial Cells which Activates PI 3-kinase by Phosphotyrosine-Independent Pathway. ASH, San Francisco, CA, 2000, Blood, 456a

15- Kagawa, T., Misra, S., Arias, I.M., Varticovski, L., Mechanism for activation of PI 3-kinase by cAMP in cell lines and canalicular membrane vesicles. TUSM, Boston, MA. AASLD, Dallas, TX, 2000

16- Antonucci J.V., I E. de Aos, T. Oo and L. Varticovski. STI571 Inhibition of BCR/ABL Transformed Cells is Potentiated by Hyprthermia. ASH, San Francisco, CA, 2000, Blood, 346a

17- Ana Robles, Curtis Harris, and Lyuba Varticovski Testing Molecular Targeted Therapies in p53-Isogenic Cell Lines, Keystone Symposia, Mol Targets for Cancer Therapeutics, 01/2005

18- Varticovski, L., Richardson, M, Robles, AI Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 inhibitors Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 23;16S, 2005: 3202 2006

19- Calcagno AM, Fostel KW, To C, Salcido CD, MartinE, ChewningKJ, WuCP, VarticovskiL, BatesS, CaplenNJ, and Ambudkar SV. ABCG2 mediates the early stages of multidrug resistance in breast, ovarian and colon cancer cells. 2007

20- Eloisi Caldas Lopes, Leandro Cerchietti, Ana I. Robles, Lyuba Varticovski, Ari Melnick, and Gabriela Chiosis In vivo antitumor efficacy of purine-scaffold Hsp90 inhibitors in basal-like breast cancer. AACR, 2008

21- Eloisi Caldas-Lopes¹, Mollie H. Wright², Gabriela Chiosis¹, Lyuba Varticovski²and Ana I. Robles Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin and Etoposide in Non-Hodgkin’s Lymphoma Cell lines. TAT Meeting, Washington, DC March, 2008

Invited Talks

03/2008 “The changing paradigm of cancer stem cells and tumor-initiating cells” Demystifying Medicine for PhD, NIH, Bethesda, MD

11/2007 “The search for mouse breast cancer stem cells”, Breast Cancer Stem Cell Interest Group, NCI, Bethesda, MD

7/2007 “Characterization of lung cancer stem cells”, Lung Cancer Interest Group, NCI, Bethesda, MD

6/2007 “Disease Models in Cancer”, World Pharmaceutical Congress, Philadelphia, PA

3/2007 ”Rational design of clinical trials based on molecular evidence: Regulation of cell cycle by HSP90 inhibitors after DNA damaging agents” Molecular Oncology, CCR, NCI

2/2006 “Identification of a Primitive Population of NE Cells in Small Cell Lung Cancer Cells” LCB, CCR,NCI

3/2006 “Molecular analysis of antagonism and synergy between HSP90 inhibitors with DNA damaging agents” HIV and AIDS malignancies Branch Seminar, CCR, NCI

8/2006 “Drug testing in transgenic models” International Conference on Frontiers in Toxicology and Pharmacology, Chicago, IL

5/2006 “Stem Cells in Lung Cancer “, Ohio State University, OH

3/2006 “Stem Cells in Lung Cancer “, Tumor Board Suburban Hospital, Bethesda, MD

9/2006 “Isolation of cancer stem cells from ling cancer” Washington VA Hospital

11/2005 Keynote Address: Japanese Society for Gastrointestinal Cancers

9/2004 “NIH Roadmap to the Translational Research in the New Millennium”. Russian-American Medical Association. The 2d National Conference, Washington, DC.

05/2003 Lymphoma: Diseases and Advances, Demystifying Medicine, NIH, Bethesda, MD

10/2003 Keynote speaker, First Russian National Hematology Congress, Moscow, Russia

4/1999 Medical Grand Rounds, St. Elizabeth’s Medical Center, Boston, MA

7/1997 Italian Association for Advancement of Studies on Gastrointestinal Diseases, Florence, Italy

10/1996 Keynote Address: Japanese Research Society for Gastrointestinal Cancers